pharma
Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020
September 21, 2020Research and Development, Sales and Marketing Cancer, ESMO 2020, Novartis, pharma
New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of …
Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma
September 18, 2020Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma
Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …
Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data
September 15, 2020Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …
MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn
September 15, 2020Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma
MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …
Oncology research in the age of COVID-19
September 14, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, pharma
Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive …
Gilead scoops up Immunomedics in deal worth $21 billion
September 14, 2020Sales and Marketing Gilead, Immunomedics, acquisition, pharma
The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …
AstraZeneca slams brakes on COVID-19 vaccine trial over unexplained participant illness
September 9, 2020Research and Development AstraZeneca, COVID-19, pharma
Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted …
Takeda to sell another non-core portfolio for $260 million to Cheplapharm
September 8, 2020Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma
Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …
Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma
September 8, 2020Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma
New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …
Janssen’s Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia
September 7, 2020Sales and Marketing Europe, Janssen, imbruvica, pharma
The European Commission (EC) has moved to expand the existing approval of Janssen’s Imbruvica (ibrutinib) in chronic lymphocytic leukaemia (CLL) …
Meta-analysis reinforces efficacy of commercially available steroids in hospitalised COVID-19 patients
September 4, 2020Medical Communications, Research and Development COVID-19, pharma, steroids
A new meta-analysis of seven studies worldwide investigating the benefit for commercially available steroid therapies in the treatment of COVID-19 …
Akebia Therapeutics’ HIF-PH inhibitor passes efficacy goals in chronic kidney disease without dialysis, but falls short on safety
September 4, 2020Medical Communications, Research and Development Akebia Therapeutics, kidney disease, pharma, vadadustat
Akebia Therapeutics has pulled back the veil on data from the second of two Phase 3 clinical trials for its …
NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression
September 3, 2020Sales and Marketing Janssen, Spravato, depression, pharma
NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …
MHRA gives OK to Bavencio for first-line maintenance of advanced bladder cancer via the Early Access to Medicines Scheme
September 3, 2020Sales and Marketing Bavencio, MHRA, Merck, Pfizer, UK, eams, pharma
It has been revealed that Bavencio (avelumab), jointly developed by Merck KGaA and Pfizer, has been approved by the UK …
Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+
September 2, 2020Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma
Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
